Second and third line treatment options for Helicobacter pylori eradication

World Journal of Gastroenterology

Volumn 20, Issue 6, 2014, Pages 1517-1528

  Song, Mingjun ^a   Ang, Tiing Leong ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Bismuth; Drug resistance; Helicobacter pylori; Metronidazole; Microbial; Moxifloxacin; Ofloxacin; Rifabutin; Rifaximin; Salvage therapy; Sitafloxacin; Treatment failure

Indexed keywords

AMOXICILLIN; BISMUTH; CAGA PROTEIN; CLARITHROMYCIN; FURAZOLIDONE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; RIFABUTIN; RIFAXIMIN; SITAFLOXACIN; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; RIFAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DISEASE ERADICATION; DNA POLYMORPHISM; HELICOBACTER INFECTION; HUMAN; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; STOMACH ACID; STOMACH PH; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT FAILURE; DRUG COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI;

ANTI-BACTERIAL AGENTS; BISMUTH; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; RIFABUTIN; RIFAMYCINS; SALVAGE THERAPY; VIRULENCE FACTORS;

EID: 84893794138     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i6.1517     Document Type: Article

References (98)

1. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]
2. Handa O, Naito Y, Yoshikawa T. CagA protein of Helicobacter pylori: a hijacker of gastric epithelial cell signaling. Biochem Pharmacol 2007; 73: 1697-1702 [PMID: 17134680]
3. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12 [PMID: 9737564 DOI: 10.1111/j.1440-1746.1998.tb00537.x]
4. Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Jaup B, Misiewicz JJ, Pajares J, Quina M, Rauws E. Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1-2 [PMID: 9031888]
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
6. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
7. Coelho LG, Maguinilk I, Zaterka S, Parente JM, Carmo Friche Passos M, Moraes-Filho JP. 3rd Brazilian Consensus on Helicobacter pylori. Arq Gastroenterol 2013; 50: [PMID: 23748591 DOI: 10.1590/S0004-28032013005000001]
8. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, Vaz Coelho LG, Fock M, Fedail S, Cohen H, Malfertheiner P, Vakil N, Hamid S, Goh KL, Wong BC, Krabshuis J, Le Mair A. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20: 299-304 [PMID: 21961099]
9. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]
10. Coelho LG, León-Barúa R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95: 2688-2691 [PMID: 11051336 DOI: 10.1111/j.1572-0241.2000.03174.x]
11. Gisbert JP, González L, Calvet X, García N, López T, Roqué M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-1328 [PMID: 11012477 DOI: 10.1046/ j.1365-2036.2000.00809.x]
12. Yan TL, Hu QD, Zhang Q, Li YM, Liang TB. National rates of Helicobacter pylori recurrence are significantly and inversely correlated with human development index. Aliment Pharmacol Ther 2013; 37: 963-968 [PMID: 23550618 DOI: 10.1111/apt.12293]
13. Graham DY, Dore MP. Helicobacter pylori therapy demystified. Helicobacter 2011; 16: 343-345 [PMID: 21923679 DOI: 10.1111/j.1523-5378.2011.00891.x]
14. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009; 14: 86-90 [PMID: 19751432 DOI: 10.1111/j.1523-5378.2009.00714.x]
15. Kobayashi I, Saika T, Muraoka H, Murakami K, Fujioka T. Helicobacter pylori isolated from patients who later failed H. pylori eradication triple therapy readily develop resistance to clarithromycin. J Med Microbiol 2006; 55: 737-740 [PMID: 16687592 DOI: 10.1099/jmm.0.46316-0]
16. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, Reasonover AL, Hurlburt DA, Bruce MG, Sacco F, Butler JC. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-469 [PMID: 13679322 DOI: 10.7326/0003-4819139-6-200309160-00008]
17. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, Stoppino G, Cea U, Pace A, Zotti M, Morini S, Panella C, Ierardi E. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007; 59: 783-785 [PMID: 17329269 DOI: 10.1093/jac/dkm005]
18. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/ j.1365-2036.2007.03386.x]
19. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206-214 [PMID: 23241101 DOI: 10.1111/hel.12031]
20. Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011; 49: 987-993 [PMID: 22203563 DOI: 10.1007/ s12275-011-1170-6]
21. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013; 18: 274-279 [PMID: 23418857 DOI: 10.1111/hel.12046]
22. Liu G, Xu X, He L, Ding Z, Gu Y, Zhang J, Zhou L. Primary antibiotic resistance of Helicobacter pylori isolated from Beijing children. Helicobacter 2011; 16: 356-362 [PMID: 21923681 DOI: 10.1111/j.1523-5378.2011.00856.x]
23. Goh KL, Navaratnam P. High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia. Helicobacter 2011; 16: 241-245 [PMID: 21585611 DOI: 10.1111/j.1523]
24. Horiki N, Omata F, Uemura M, Suzuki S, Ishii N, Iizuka Y, Fukuda K, Fujita Y, Katsurahara M, Ito T, Cesar GE, Imoto I, Takei Y. Annual change of primary resistance to clarithromycin among Helicobacter pylori isolates from 1996 through 2008 in Japan. Helicobacter 2009; 14: 86-90 [PMID: 19751432]
25. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, Osato MS, El-Zaatari FA, Graham DY, Kwon DH. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44: 2214-2216 [PMID: 10898707]
26. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
27. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Metaanalysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008; 28: 868-877 [PMID: 18644011 DOI: 10.1111/j.1365-2036.2008.03807.x]
28. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-889 [PMID: 2512133]
29. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007; 12: 317-323 [PMID: 17669104 DOI: 10.1111/j.1523-5378.2007.00508.x]
30. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998; 43 Suppl 1: S56-S60 [PMID: 9764042]
31. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28 [PMID: 8827397]
32. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-168 [PMID: 11240980 DOI: 10.1067/mcp.2001.113959]
33. Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS, Jung HC. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage. J Gastroenterol Hepatol 2008; 23: 1287-1291 [PMID: 18637061 DOI: 10.1111/j.1440-1746.2008.05392.x]
34. Sheu BS, Fock KM. CYP2C19 genotypes and Helicobacter pylori eradication. J Gastroen Hepatol 2008; 23: 1163 [DOI: 10.1111/j.1440-1746.2008.05519.x]
35. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154 [PMID: 7648764]
36. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004; 76: 290-301 [PMID: 15470328 DOI: 10.1016/ j.clpt.2004.06.008]
37. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-1937 [PMID: 11736724 DOI: 10.1046/j.1365-2036.2001.01108.x]
38. Backert S, Selbach M. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol 2008; 10: 1573-1581 [PMID: 18410539 DOI: 10.1111/j.1462-5822.2008.01156.x]
39. Zanten SJ, Bradette M, Farley A, Leddin D, Lind T, Unge P, Bayerdörffer E, Spiller RC, O'Morain C, Sipponen P, Wrangstadh M, Zeijlon L, Sinclair P. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-295 [PMID: 10102960 DOI: 10.1046/j.1365-2036.1999.00471.x]
40. Maeda S, Yoshida H, Ikenoue T, Ogura K, Kanai F, Kato N, Shiratori Y, Omata M. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut 1999; 44: 336-341 [PMID: 10026317 DOI: 10.1136/gut.44.3.336]
41. van Doorn LJ, Schneeberger PM, Nouhan N, Plaisier AP, Quint WG, de Boer WA. Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment. Gut 2000; 46: 321-326 [PMID: 10673291 DOI: 10.1136/ gut.46.3.321]
42. Wang M, Furuta T, Takashima M, Futami H, Shirai N, Hanai H, Kaneko E. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J Gastroenterol 1999; 34 Suppl 11: 10-17 [PMID: 10616759]
43. Furuta T, El-Omar EM, Xiao F, Shirai N, Takashima M, Sugimura H. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002; 123: 92-105 [PMID: 12105837 DOI: 10.1053/gast.2002.34156]
44. Atherton JC, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771-17777 [PMID: 7629077 DOI: 10.1074/jbc.270.30.17771]
45. Cover TL, Tummuru MK, Cao P, Thompson SA, Blaser MJ. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J Biol Chem 1994; 269: 10566-10573 [PMID: 8144644]
46. Letley DP, Atherton JC. Natural diversity in the N terminus of the mature vacuolating cytotoxin of Helicobacter pylori determines cytotoxin activity. J Bacteriol 2000; 182: 3278-3280 [PMID: 10809711]
47. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 2009; 57: 45-56 [PMID: 19219527 DOI: 10.1007/s00005-009-0007-z]
48. Furuta T, Shirai N, Xiao F, El-Omar EM, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K. Polymorphism of interleukin1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004; 2: 22-30 [PMID: 15017629]
49. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther 2006; 80: 41-50 [PMID: 16815316 DOI: 10.1016/j.clpt.2006.03.007]
50. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609 [PMID: 10792124 DOI: 10.1046/j.1365-2036.2000.00744.x]
51. Abdullahi M, Annibale B, Capoccia D, Tari R, Lahner E, Osborn J, Leonetti F, Severi C. The eradication of Helicobacter pylori is affected by body mass index (BMI). Obes Surg 2008; 18: 1450-1454 [PMID: 18443890 DOI: 10.1007/s11695-0089477-z]
52. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, Tajima K. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217-224 [PMID: 16490464]
53. Zullo A, De Francesco V, Hassan C. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks! J Clin Gastroenterol 2012; 46: 259-261 [PMID: 22395061 DOI: 10.1097/MCG.0b013e318247177e]
54. Ang TL, Fock KM, Ng TM, Teo EK, Chua TS, Tan YL. Efficacy of quadruple therapy for Helicobacter pylori eradication after failure of proton pump inhibitor-based triple therapy in Singapore. Zhongguo Xiaohua Jibing Zazhi 2003; 4: 35-39 [DOI: 10.1046/j.1443-9573.2003.00102.x]
55. Marin AC, McNicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14: 843-861 [PMID: 23537368 DOI: 10.1517 /14656566.2013.782286]
56. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002; 16: 1047-1057 [PMID: 12030945 DOI: 10.1046/j.1365-2036.2002.01276.x]
57. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, openlabel, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60020-2]
58. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spénard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003; 98: 562-567 [PMID: 12650788]
59. Muller N, Delchier JC. Rescue Treatment With Quadruple Therapy (3-in-1 Capsule of Bismuth, Metronidazole and Tetracycline With Omeprazole) for H Pylori in Patients With Multi-Drug Resistance to Clarithromycin, Fluoroquinolones and Metronidazole: Preliminary Data. Gastroenterology 2011; 5 supp1: S-879
60. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44 [PMID: 16393278 DOI: 10.1111/j.1365-2036.2006.02737.x]
61. Di Caro S, Fini L, Daoud Y, Grizzi F, Gasbarrini A, De Lorenzo A, Di Renzo L, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol 2012; 18: 5669-5678 [PMID: 23155306 DOI: 10.3748/wjg. v18.i40.5669]
62. Moon JY, Kim GH, You HS, Lee BE, Ryu DY, Cheong JH, Jung JI, Jeong JH, Song CS, Song GA. Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea. Gut Liver 2013; 7: 406-410 [PMID: 23898379 DOI: 10.5009/gnl.2013.7.4.406]
63. Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother 2013; 68: 222-228 [PMID: 22984204 DOI: 10.1093/ jac/dks361]
64. Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013; 48: 652-656 [PMID: 23556551 DOI: 10.3109/00365521.2013.786132]
65. Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC; Taiwan Acid-Related Disease (TARD) Study Group. Ten-Day Quadruple Therapy Comprising Proton-Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for Helicobacter pylori Infection after Failure of Sequential Therapy. Helicobacter 2014; 19: 74-79 [PMID: 24033865 DOI: 10.1111/hel.12085]
66. Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol 2009; 24: 1155-1157 [PMID: 19682186 DOI: 10.1111/j.1440-1746.2009.05911.x]
67. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, Lopes AI, Ramalho P, Neves BC, Guerreiro AS. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-1031 [PMID: 11102427 DOI: 10.1093/jac/46.6.1029]
68. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 538-541 [PMID: 10968325 DOI: 10.1007/s100960000288]
69. Cuadrado-Lavín A, Salcines-Caviedes JR, Carrascosa MF, Mellado P, Monteagudo I, Llorca J, Cobo M, Campos MR, Ayestarán B, Fernández-Pousa A, González-Colominas E. Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. J Antimicrob Chemother 2012; 67: 170-173 [PMID: 21965436 DOI: 10.1093/jac/dkr410]
70. Vécsei A, Kipet A, Innerhofer A, Graf U, Binder C, Gizci H, Hammer K, Bruckdorfer A, Huber WD, Hirschl AM, Makristathis A. Time trends of Helicobacter pylori resistance to antibiotics in children living in Vienna, Austria. Helicobacter 2010; 15: 214-220 [PMID: 20557363 DOI: 10.1111/ j.1523-5378.2010.00753.x]
71. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14 years of clinical data. Drugs R D 2012; 12: 71-100 [PMID: 22715866 DOI: 10.2165/11634300-000000000-0 0000]
72. Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter 2011; 16: 131-138 [PMID: 21435091 DOI: 10.1111/j.1523-5378.2011.00826.x]
73. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, Laass MW, Neumeyer M, Jebens C, Zekorn C, Knoth H, Vieth M, Stolte M, Lehn N, Morgner A. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011; 16: 420-426 [PMID: 22059392 DOI: 10.1111/j.1523-5378.2011.00867.x]
74. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-718 [PMID: 10848654 DOI: 10.1046/j.1365-2036.2000.00766.x]
75. Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2011; 66: 1847-1852 [PMID: 21632579 DOI: 10.1093/jac/ dkr217]
76. Matsumoto Y, Miki I, Aoyama N, Shirasaka D, Watanabe Y, Morita Y, Toyoda M, Mitani T, Miyachi H, Tamura T, Kasuga M. Levofloxacinversus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis 2005; 37: 821-825 [PMID: 16040284]
77. Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012; 17: 216-223 [PMID: 22515360 DOI: 10.1111/ j.1523-5378.2012.00937.x]
78. Hori K, Miwa H, Matsumoto T. Efficacy of 2-week, secondline Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population. Helicobacter 2011; 16: 234-240 [PMID: 21585610 DOI: 10.1111/j.1523-5378.2011.00842.x]
79. Gasbarrini A, Ojetti V, Armuzzi A, Branca G, Canducci F, Torre ES, Candelli M, Pastorelli A, Anti M, Fedeli G, Fadda G, Pola P, Gasbarrini G. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 79-83 [PMID: 10632649 DOI: 10.1046/ j.1365-2036.2000.00685.x]
80. Chan FK, Sung JJ, Suen R, Wu JC, Ling TK, Chung SC. Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Aliment Pharmacol Ther 2000; 14: 91-95 [PMID: 10632651 DOI: 10.1046/j.1365-2036.2000.00674.x]
81. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001 [PMID: 17854602 DOI: 10.1053/j.gastro.2007.07.008]
82. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-456 [PMID: 23099849 DOI: 10.1093/jac/ dks407]
83. González Carro P, Pérez Roldán F, De Pedro Esteban A, Legaz Huidobro ML, Soto Fernández S, Roncero Garcia Escribano O, Esteban López-Jamar JM, Pedraza Martin C, Ruíz Carrillo F. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007; 22: 60-63 [PMID: 17201882]
84. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 35: 209-221 [PMID: 22129228 DOI: 10.1111/j.1365-2036.2011.04937.x]
85. Perri F, Festa V, Clemente R, Villani MR, Quitadamo M, Caruso N, Bergoli ML, Andriulli A. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 2001; 96: 58-62 [PMID: 11197288]
86. Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11: 507-510 [PMID: 23267869 DOI: 10.1016/j.cgh.2012.12.007]
87. Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H, Saito Y, Kobayashi I, Hibi T. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion 2009; 79: 1-4 [PMID: 19142036 DOI: 10.1159/000191204]
88. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl 1: 36-66 [PMID: 15855748]
89. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion 2006; 73 Suppl 1: 129-135 [PMID: 16498261]
90. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, Kwon CI, Ko KH, Hwang SG, Park PW, Hong SP. Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori. Gut Liver 2012; 6: 452-456 [PMID: 23170149 DOI: 10.5009/gnl.2012.6.4.452]
91. Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS, El-Zimaity HM. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005-1009 [PMID: 12809820 DOI: 10.1111/j.1572-0241.2003.07426.x]
92. Tursi A, Picchio M, Elisei W. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis 2012; 21: 133-138 [PMID: 22720300]
93. Zullo A, Hassan C, De Francesco V, Lorenzetti R, Marignani M, Angeletti S, Ierardi E, Morini S. A third-line levofloxacinbased rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 232-236 [PMID: 12801033]
94. Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, Nomura H, Satoh K, Hori S, Inoue S, Tomokane T, Kudo M, Inaba T, Take S, Ohkusa T, Yamamoto S, Mizuno S, Kamoshida T, Amagai K, Iwamoto J, Miwa J, Kodama M, Okimoto T, Kato M, Asaka M. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol 2013; 48: 1128-1135 [PMID: 23307042 DOI: 10.1007/s00535-012-0731-8]
95. Suzuki H, Nishizawa T, Muraoka H, Hibi T. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation. Antimicrob Agents Chemother 2009; 53: 1720-1721 [PMID: 19188389 DOI: 10.1128/AAC.00049-09]
96. Hirata Y, Ohmae T, Yanai A, Sakitani K, Hayakawa Y, Yoshida S, Sugimoto T, Mitsuno Y, Akanuma M, Yamaji Y, Ogura K, Maeda S, Koike K. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents 2012; 39: 352-355 [PMID: 22321702 DOI: 10.1016/j.ijantimicag.2011. 12.002]
97. Matsuzaki J, Suzuki H, Nishizawa T, Hirata K, Tsugawa H, Saito Y, Okada S, Fukuhara S, Hibi T. Efficacy of sitafloxacinbased rescue therapy for Helicobacter pylori after failures of firstand second-line therapies. Antimicrob Agents Chemother 2012; 56: 1643-1645 [PMID: 22203601 DOI: 10.1128/ AAC.05941-11]
98. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M, Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008; 135: 787-795 [PMID: 18619971 DOI: 10.1053/j.gastro.2008.05.054]